about   CII home   shop   checkout

Detecting the Undetectable Development and Validation of Ultrasensitive Simoa-Based Assays to Reproducibly Measure Immune System Regulatory Proteins in Human Blood Samples




June 30, 2015
11:00 am to 12:00 pm EDT

 

Sponsored by
MYRIAD-RBM  

Webinar Description:

Quanterix’s ultrasensitive single molecule array (Simoa) technology enables the accurate measurement of protein biomarkers that were previously difficult or even impossible to detect in blood samples. Myriad RBM, a leader in immunoassay testing services, has developed and validated Simoa-based assay services with carefully designed calibrators and controls to ensure quality, precision and accuracy. These reproducible assays, offered as a service in Myriad RBM’s CLIA certified lab, can measure proteins at the femtogram per mL level, detecting important immune modulating proteins in serum and plasma from normal individuals. This unprecedented sensitivity has the potential to revolutionize clinical research in multiple therapeutic areas including immuno-oncology, autoimmune disorders, cardiovascular diseases and other research focusing on inflammatory processes.

Learning Objectives:

  • Learn about the design and validation of Myriad RBM’s Simoa assay services
  • See demonstration of the ultrasensitive service’s capability to reproducibly measure cytokines in normal samples
  • Explore the applications and understand how to utilize this service in your clinical research

Speaker:

Dominic Eisinger, Ph.D.

Vice President of Sales and Marketing

Myriad RBM

Dominic Eisinger, PhD, is a member of the business and scientific management team at Myriad RBM. Prior to joining Myriad RBM he was President of Multiplex Biosciences, a multiplex immunoassay development and manufacturing company he started. Dr. Eisinger has also held previous management positions in R&D related to multiplex immunoassay development, molecular biology and tumor vaccine antigen discovery. He has over 18 years industry experience in various scientific and commercialization roles and is a noted international authority on protein arrays. Dr. Eisinger has B.S. in biochemistry from Cornell University and a PhD in molecular biology from the University of Vermont prior to completing post-doctoral training at Dartmouth Medical School.



Download Webinar